drugset
drugset / Trial / NCT05217693

A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors

NCT05217693 ↗

Phase 1 Recruiting 288 enrolled Bliss Biopharmaceutical (Hangzhou) Co., Ltd
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The study consists of two phases: dose-escalation (Phase I) and cohort expansion (Phase II).

Timeline

Start
2022-06-01
Primary completion
2025-06-01
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject BB-1705 Monoclonal antibody — Intravenous

Indications

cancer